Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
Vericel (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. ET (7:30 a.m. PT).
Interested parties can access a webcast of the presentation through the Investor Relations section of Vericel's website at http://investors.vcel.com.
Vericel (NASDAQ:VCEL), un fornitore leader di terapie avanzate per la medicina sportiva e la cura di gravi ustioni, ha annunciato la sua prossima presentazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La presentazione è prevista per mercoledì 15 gennaio 2025, alle 10:30 ET (7:30 PT).
Le parti interessate possono accedere a una webcast della presentazione tramite la sezione Relazioni con gli Investitori del sito web di Vericel all'indirizzo http://investors.vcel.com.
Vericel (NASDAQ:VCEL), un proveedor líder de terapias avanzadas para la medicina deportiva y el cuidado de quemaduras severas, ha anunciado su próxima presentación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. La presentación está programada para miércoles 15 de enero de 2025, a las 10:30 a.m. ET (7:30 a.m. PT).
Las partes interesadas pueden acceder a una transmisión por webcast de la presentación a través de la sección de Relaciones con Inversores en el sitio web de Vericel en http://investors.vcel.com.
Vericel (NASDAQ:VCEL), 스포츠 의학 및 심각한 화상 치료를 위한 첨단 치료제의 선두 제공업체가 제43회 J.P. 모건 헬스케어 콘퍼런스에서 발표할 예정임을 발표했습니다. 발표는 2025년 1월 15일 수요일, 오전 10시 30분 ET (오전 7시 30분 PT)로 예정되어 있습니다.
관심 있는 분들은 Vericel의 웹사이트 투자자 관계 섹션을 통해 발표의 웹캐스트에 접근할 수 있습니다: http://investors.vcel.com.
Vericel (NASDAQ:VCEL), un fournisseur leader de thérapies avancées pour la médecine du sport et les soins des brûlures graves, a annoncé sa prochaine présentation lors de la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour mercredi 15 janvier 2025 à 10h30 ET (7h30 PT).
Les parties intéressées peuvent accéder à un webcast de la présentation via la section Relations Investisseurs du site web de Vericel à l'adresse http://investors.vcel.com.
Vericel (NASDAQ:VCEL), ein führender Anbieter von fortschrittlichen Therapien für Sportmedizin und die Behandlung schwerer Brandverletzungen, hat seine bevorstehende Präsentation auf der 43. J.P. Morgan Healthcare Conference angekündigt. Die Präsentation ist für Mittwoch, den 15. Januar 2025, um 10:30 Uhr ET (7:30 Uhr PT) geplant.
Interessierte Parteien können über den Bereich Investor Relations auf der Website von Vericel unter http://investors.vcel.com auf einen Webcast der Präsentation zugreifen.
- None.
- None.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When is Vericel (VCEL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Vericel's (VCEL) J.P. Morgan Healthcare Conference presentation?
What markets does Vericel (VCEL) operate in?
Which annual healthcare conference is Vericel (VCEL) participating in for 2025?
